Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in cancer. The company’s news flow centers on the development of its lead program, silevertinib (also known as BDTX-1535), a brain-penetrant fourth-generation EGFR MasterKey inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
On this page, readers can follow company announcements related to clinical trial progress, including Phase 2 data updates in frontline NSCLC patients with non-classical EGFR mutations and investigator-sponsored studies in EGFR-altered GBM. Black Diamond’s releases describe objective response rates, CNS activity, duration of treatment or response, and plans for randomized Phase 2 trials in newly diagnosed GBM patients.
News items also cover corporate and financial updates, such as quarterly and annual financial results, cash runway commentary, and strategic priorities around advancing silevertinib. In addition, Black Diamond reports on business development activities, including a global licensing agreement with Servier for BDTX-4933, a Phase 1 therapy designed to target RAF/RAS-mutant solid tumors.
Investors and observers can use this news feed to track webcast and conference presentations, regulatory and development plans in NSCLC and GBM, and partnership discussions around pivotal development. Regular updates provide insight into how Black Diamond Therapeutics is progressing its MasterKey therapies across genetically defined tumor types and CNS-involved disease.
Black Diamond Therapeutics has published findings revealing 22 new oncogenic HER2 driver mutations discovered through its MAP discovery engine. The research, appearing in the AACR's Cancer Research Journal, emphasizes the importance of identifying these mutations for developing novel inhibitors aimed at treating HER2-mutant cancers. The study validated 37 HER2 driver mutations from 820 variants analyzed, demonstrating Black Diamond's capacity for drug discovery focused on precision oncology. This advancement highlights the necessity of innovative treatment options for patients with specific genetic profiles.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the dosing of the first patient in the Phase 1 study of BDTX-1535 for glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). The company reported financial results for Q1 2022, highlighting a cash position of approximately $179.7 million, down from $209.8 million in Q4 2021. R&D expenses decreased to $17.8 million, while net loss narrowed to $25.5 million from $30.3 million year-over-year. The company extends its cash runway into Q3 2024, emphasizing its strategic focus on BDTX-1535 and BDTX-4933.
Black Diamond Therapeutics (NASDAQ: BDTX) announced a strategic realignment to enhance operational efficiency and extend its cash runway into Q3 2024. The company will discontinue the development of BDTX-189 and reduce its workforce by approximately 30%. Focus will shift to advancing key programs BDTX-1535 and BDTX-4933, aimed at addressing unmet needs in precision oncology. BDTX-1535 is in Phase 1 development for glioblastoma, while BDTX-4933 is undergoing IND-enabling studies. These moves are expected to support significant upcoming clinical milestones.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the dosing of the first patient in its Phase 1 clinical study of BDTX-1535, a MasterKey inhibitor targeting EGFR mutations in non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The trial aims to address the unmet needs of patients with these conditions, especially those resistant to current treatments. BDTX-1535 is anticipated to benefit over 60,000 GBM patients annually in key markets, with updates expected in the second half of 2023. The company utilizes its MAP drug discovery engine to develop precision oncology therapies.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced that its President and CEO, David M. Epstein, Ph.D., will give a presentation on the company’s advancements at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14, 2022, at 10:00 a.m. ET. Interested parties can access a live webcast of the discussion through the investor relations section of Black Diamond's website. The company specializes in precision oncology and is focused on developing novel MasterKey therapies for patients with genetically defined cancers.
Black Diamond Therapeutics (BDTX) announced the appointment of Wendy L. Dixon, Ph.D., to its Board of Directors following the resignation of Brad Bolzon, Ph.D. This change aims to bolster the company's leadership as it advances its MasterKey therapies. Dr. Dixon, with over 40 years of experience in the biopharmaceutical industry and a strong background in marketing and drug development, is expected to enhance strategic initiatives, particularly in the ongoing clinical development of BDTX-1535 for glioblastoma multiforme. Dr. Epstein praised Bolzon's contributions during his tenure.
Black Diamond Therapeutics (BDTX) reported significant developments, including the initiation of a Phase 1 study for BDTX-1535, targeting glioblastoma and non-small cell lung cancer, after receiving FDA IND approval. As of December 31, 2021, the company held $209.8 million in cash, sufficient for operations into 2024. R&D expenses nearly doubled to $96.8 million due to increased headcount and clinical activities. The net loss for the year was $125.6 million, up from $67.3 million in 2020. Elizabeth Montgomery was appointed Chief People Officer, enhancing HR leadership in the company.
Black Diamond Therapeutics (Nasdaq: BDTX) announces participation in the Cowen 42nd Annual Health Care Conference. Its CEO, David M. Epstein, Ph.D., will join a panel on lung cancer on March 9, 2022, at 9:10 a.m. ET. A live webcast of the discussion will be available on the company’s website, with a replay accessible for 30 days. Black Diamond is focused on developing novel MasterKey therapies for patients with genetically defined cancers, leveraging its MAP drug discovery engine to target oncogenic mutations.
Black Diamond Therapeutics (Nasdaq: BDTX) has appointed Elizabeth Montgomery as its first Chief People Officer. With nearly 20 years of HR leadership experience in the life sciences industry, Montgomery will play a vital role in shaping the company's people and talent strategy. Her previous role at ClearView Healthcare Partners saw significant growth and expansion. Montgomery expressed her enthusiasm for Black Diamond's mission to enhance precision cancer therapies, promising to foster an inclusive workplace culture that encourages creativity and growth.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that the FDA has cleared its investigational new drug (IND) application for BDTX-1535, a targeted therapy for oncogenic mutations in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). The Phase 1 study is set to start in Q1 2022, with a clinical update expected in H2 2023. BDTX-1535 aims to meet the needs of over 60,000 GBM patients and 20,000 NSCLC patients annually in major markets, showing promising preclinical results in tumor regression without affecting body weight.